Outsourced microbiological support to hospital-based surveillance of CDI aims to increase the capacity of laboratories in EU/EEA Member States to perform diagnostic practices with high diagnostic accuracy and acquire comparable typing data from C. difficile isolates.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 September 2023 and includes updates on COVID-19, diphtheria, West Nile virus, avian influenza, dengue, legionnaires' disease, the Rugby World Cup 2023, cutaneous Anthrax, pertussis, botulism and severe floods.
To improve the understanding of experienced HIV stigma in the community, ECDC initiated an exploratory survey in 2021 to measure HIV-related stigma across Europe and Central Asia.
This evidence brief summarises the progress towards UN Sustainable Development Goal 3.3 to ‘eliminate the epidemic of AIDS’ in Europe and Central Asia.
Progress towards ending the AIDS epidemic by 2030 is variable across the region, and most countries in Europe and Central Asia are currently far from achieving the 2025 targets.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 20-26 August and includes updates on avian influenza, botulism, autochthonous dengue, Legionnaires' disease, COVID-19, West Nile virus, Chikungunya and dengue.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 13-19 August and includes updates on avian influenza A(H5N6), avian influenza A(H9N2), West Nile virus, COVID-19, poliomyelitis, and Crimean-Congo haemorrhagic fever.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 6 - 12 August 2023 and includes updates on measles, COVID-19, swine flu, mpox, diphtheria, West Nile virus, avian influenza, dengue, Crimean-Congo haemorrhagic fever, and invasive meningococcal disease.